Enento Group Plc: SHARE REPURCHASE 15.5.2023
|Enento Group Plc||ANNOUNCEMENT||15.5.2023|
|Enento Group Plc: SHARE REPURCHASE 15.5.2023|
|In the Helsinki Stock Exchange|
|Average price/ share||19.1694||EUR|
|Enento Group Plc now holds a total of 73 700 shares|
|including the shares repurchased on 15.5.2023|
|On behalf of Enento Group Plc|
|Nordea Bank Oyj|
|Janne Sarvikivi||Sami Huttunen|
|For further information:|
|Investor Relations Officer|
|tel. +358 50 469 5380|
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Correction: Avance Gas Holding Ltd: Key information relating to the dividend for the first quarter 202330.5.2023 15:30:30 CEST | Press release
Bermuda, May 30 2023 Please note that the record date has been included to the below key information relating to dividend for the first quarter 2023. Key information relating to the dividend to be paid by Avance Gas Holding Ltd. for the first quarter 2023: Dividend amount: $0.50 Declared currency: USD Last day including right: June 6, 2023 Ex-date: June 7, 2023 Record date: June 8, 2023 Payment date: June 14, 2023 Date of Approval: May 29, 2023 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control30.5.2023 15:30:00 CEST | Press release
Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control Proposal to appoint Jonathan Milner Executive Chairman of the Board Proposal to remove Peter Allen, Michael Baldock, and Sally Crawford as Directors of the Company ExecutiveChairman Milner intends torestore Abcam to the valuation it deserves CAMBRIDGE, England, 30May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.3% of the Company, announced today that he has formally requisitioned the Board of Directors to convene an extraordinary general meeting of shareholders (“EGM”) to reverse a period of sustained financial and operational underperformance by providing more effective Board level leadership for the Company. The EGM will enable shareholders to vote on the following proposals: The removal of Peter Allen, Michael Baldock, and Sally Crawford from office as Directors of the
PHARMANOVIA ENTERS NEW CHEMICAL ENTITY LICENSING AGREEMENT WITH STEALTH BIOTHERAPEUTICS TO MARKET AND FURTHER DEVELOP A POTENTIAL NOVEL TREATMENT FOR BARTH SYNDROME30.5.2023 15:25:24 CEST | Press release
Basildon, UK, May 30, 2023 (GLOBE NEWSWIRE) -- PRESS RELEASE - FOR BUSINESS & TRADE MEDIA ONLY THE AGREEMENT COVERS RIGHTS FOR ELAMIPRETIDE FOR BARTH SYNDROME IN THE EU, NORWAY, SWITZERLAND, UK, ICELAND, AND MIDDLE EAST & NORTH AFRICA (MENA) TERRITORIESTHERE ARE NO CURRENT APPROVED TREATMENTS FOR BARTH SYNDROMETHIRD NEW CHEMICAL ENTITY DEAL FOR PHARMANOVIA, EXPANDING PORTFOLIO IN CARDIOLOGY AND RARE DISEASES Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its cardiology portfolio through a new licensing agreement with US-based biopharmaceutical company, Stealth BioTherapeutics Inc. The agreement gives Pharmanovia the licensing rights to elamipretide for Barth syndrome in Europe and MENA. This is a significant milestone as ongoing studies indicate that elamipretide has the potential to improve the quality of life for people with Barth syndrom
Golar releases its 2022 Environmental, Social and Governance report30.5.2023 15:23:39 CEST | Press release
Golar LNG Limited (“Golar”) is pleased to announce that it has issued its 2022 Environmental, Social and Governance (“ESG”) report. This comprehensive report describes Golar’s important role in advancing the global energy transition to a lower carbon future - championing LNG as a transition fuel in partnership with renewables, and as a reliable alternative for those in need of energy security today. Our 2022 ESG report is attached and will also be posted to our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended). All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negat
Awilco Drilling PLC: Notice of Annual General Meeting 202330.5.2023 15:15:00 CEST | Press release
The Annual General Meeting of Awilco Drilling PLC will be held Monday 26 June 2023 at 12:00 noon (UK time), at the offices of Awilco Drilling on 2 Kingshill Park, Venture Drive, Arnhall Business Park, Westhill, Aberdeen, AB32 6FL, UK. The notice including agenda for the General Meeting is attached to this disclosure. The notice will be sent by mail or e-mail to the shareholders. The notice and appendices have been made available on our website www.awilcodrilling.com. Aberdeen, 30 May 2023 For further information please contact: Eric Jacobs, Interim CEO Phone: +44 1224 737900 Cathrine Haavind, Investor Relations Phone: +47 93 42 84 64 Email: email@example.com This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment AWDR AGM Notice 2023